Nuwellis, Inc. Announces Results of Special Shareholder Meeting: Key Proposals Approved
Eden Prairie, MN, July 24, 2026 – Nuwellis, Inc. (NASDAQ: NUWE), a medical technology company, today announced the results of a special meeting of shareholders held virtually via live webcast. The meeting brought several critical proposals to a vote, with major implications for the company’s capital structure, continued Nasdaq listing, and future financing flexibility.
Key Highlights from the Special Meeting
- Approval of Share Issuance Under Nasdaq Rule 5635(d): Shareholders voted to approve the issuance of common stock pursuant to the exercise of warrants sold in the company’s recent financing transaction (closed June 8, 2026), as well as outstanding warrants that were repriced in connection with that financing. This approval is in accordance with Nasdaq Listing Rule 5635(d) and related interpretations.
- Reverse Stock Split Authorization: Shareholders approved an amendment to the company’s Fourth Amended and Restated Certificate of Incorporation, giving the Board of Directors the authority to effect a reverse stock split of outstanding common shares within a ratio range of 1-for-5 up to 1-for-70. This measure is aimed at enabling the company to comply with Nasdaq’s continued listing requirements. The Board may implement the split at its discretion within 12 months of shareholder approval.
- Adjournment Flexibility: Shareholders authorized one or more adjournments of the special meeting to solicit additional proxies if necessary to approve the first two proposals. This measure provides the company flexibility in ensuring the passage of these critical proposals if initial voting thresholds are not met.
Detailed Voting Results
A total of 1,490,999 shares (approximately 46.2% of outstanding shares) were present in person or by proxy at the meeting. The breakdown for each proposal is as follows:
- Proposal 1 – Share Issuance for Warrant Exercise:
- Votes For: 216,196
- Votes Against: 250
- Result: Approved
This approval allows Nuwellis to issue additional shares upon the exercise of warrants from the June 8 financing and repricing transaction, potentially increasing the company’s outstanding shares and raising additional capital.
- Proposal 2 – Reverse Stock Split Authorization:
- Votes For: 1,172,689
- Votes Against: 310,588
- Abstentions: 7,722
- Result: Approved
This measure gives the Board broad authority to consolidate the company’s shares within a 1-for-5 to 1-for-70 range, a critical step to maintaining Nasdaq listing compliance should the share price fall below minimum requirements.
- Proposal 3 – Adjournment Authorization:
- Votes For: 1,182,933
- Votes Against: 307,722
- Abstentions: 344
- Result: Approved
This provides flexibility for future adjournments to secure necessary votes for critical proposals.
What Investors Need to Know
- Potential Share Price Impact: The approval of a reverse stock split is a significant move that can affect the market price of Nuwellis shares. Historically, reverse splits can increase the per-share price but reduce the number of shares outstanding. The actual ratio and timing are at the Board’s discretion within the next 12 months.
- Nasdaq Listing Compliance: The reverse split authorization is directly tied to maintaining compliance with Nasdaq’s minimum bid price and other listing requirements. Failure to implement a reverse split, if needed, could put the company’s listing at risk.
- Future Dilution: The approval to issue shares upon warrant exercises means shareholders could face dilution as warrants are exercised, increasing the total number of outstanding shares. However, this also provides the company with additional capital, which may be necessary for growth or operational stability.
- Shareholder Participation: Only 46.2% of shares were represented at the meeting, underscoring the importance of active shareholder engagement in determining the company’s strategic direction.
Corporate Signature
The report was signed on behalf of the company by Michael McCormick, President and Chief Executive Officer, on July 24, 2026.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review official filings and consult with their financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
